Dr Lalchandani Labs Ltd

Dr Lalchand. Lab has experienced a decline in net sales and profitability, with total operating income dropping from 11.28 Cr in Mar'22 to 4.45 Cr in Mar'25, and profit before tax decreasing from 1.25 Cr to 0.40 Cr in the same period. Total assets and liabilities also decreased, while cash flow from operating activities remained stagnant, though a net cash inflow of 1.00 Cr was recorded in Mar'25.

Dr Lalchand. Lab will announce its results on 14 November 2025.

As of 10-Nov, Dr Lalchandani Labs Ltd's stock price is Rs 20.23, down 4.98%, underperforming its sector and showing erratic trading patterns with decreased investor participation. Despite a year-to-date increase of 19.70%, its long-term performance has declined significantly compared to the broader market.

As of 08-Oct, Dr Lalchandani Labs Ltd's stock price has declined to Rs 21.58, down 4.98%, and has underperformed its sector and the benchmark Sensex. Despite a year-to-date increase of 27.69%, recent trading activity has been erratic, with significant losses over the past week and month.

As of 22-Sep, Dr Lalchandani Labs Ltd's stock price is at 23.90, showing a recent rebound after a decline, but it has underperformed in the short term with a 1-week return of -8.01%. Despite this, it has strong long-term performance with a year-to-date increase of 41.42%, although declining investor participation raises concerns about liquidity.

As of September 19, 2025, Dr Lalchand Lab is considered undervalued with a PE ratio of 9.97 and an EV to EBITDA of 10.33, significantly lower than peers like Apollo Hospitals and Max Healthcare, and has outperformed the Sensex with a year-to-date return of 36.15%.

As of September 19, 2025, Dr Lalchand Lab is considered undervalued with a PE ratio of 9.97, significantly lower than industry peers like Apollo Hospitals and Max Healthcare, and despite recent short-term underperformance, its year-to-date return of 36.15% suggests strong growth potential.

As of September 19, 2025, Dr Lalchand Lab is considered undervalued with a PE ratio of 9.97 and an EV to EBITDA of 10.33, significantly lower than peers like Apollo Hospitals and Max Healthcare, while achieving a year-to-date return of 36.15%, outperforming the Sensex's 5.74%.

As of 19-Sep, Dr Lalchandani Labs Ltd's stock price has declined to Rs 23.01, down 5.0%, with a significant drop of 11.43% over the past week and reduced investor participation. Despite a year-to-date increase of 36.15%, the stock is underperforming against the sector and overall market trends, indicating waning investor confidence.

As of 18-Sep, Dr Lalchandani Labs Ltd's stock price is Rs 24.22, down 6.77% today and underperforming its sector. Despite a strong year-to-date increase of 43.31%, recent declines indicate declining investor confidence and liquidity issues.

As of September 17, 2025, Dr Lalchand Lab is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 11.26 and an EV to EBITDA of 11.82, despite outperforming the Sensex year-to-date with a return of 53.73%.

As of September 16, 2025, Dr Lalchand Lab is considered very expensive and overvalued with a PE ratio of 11.26 and an EV to EBITDA ratio of 11.82, despite a strong year-to-date return of 53.73%, especially when compared to peers like Apollo Hospitals, Max Healthcare, and Fortis Health.

As of September 15, 2025, Dr Lalchand Lab is considered expensive and overvalued with a PE ratio of 11.26 and an EV to EBITDA of 11.82, especially when compared to peers like Max Healthcare and Apollo Hospitals, despite a strong year-to-date stock return of 53.73%.

As of September 10, 2025, Dr Lalchand Lab is considered very expensive and overvalued compared to its peers, despite a strong year-to-date return of 53.73%, indicating it may not be a favorable investment at this time.

As of 09-Sep, Dr Lalchandani Labs Ltd's stock price is 25.98, reflecting a slight decline of 0.04%. Despite recent underperformance, the stock has gained 35.52% over the past month and remains above key moving averages, although it has not traded on 3 of the last 20 days.

As of 03-September, Dr Lalchandani Labs Ltd's stock price is Rs 25.99, down 4.97% after reaching a 52-week high. Despite a strong year-to-date performance of 53.79%, recent profit-taking and a drop in delivery volume may indicate declining investor confidence.

As of 02-September, Dr Lalchandani Labs Ltd's stock price is Rs. 27.35, up 2.09%, with a recent 52-week high of Rs. 27.5 and a 17.53% gain over the last four days. The stock is trading above all key moving averages and has seen a 150% increase in delivery volume, indicating strong investor interest and outperforming the Sensex significantly.

As of 01-Sep, Dr Lalchandani Labs Ltd's stock price is rising, currently at Rs. 26.79, reflecting a 4.98% increase. The stock has outperformed the benchmark Sensex significantly, gaining 58.52% year-to-date, despite a slight decline in investor participation.

As of 29-Aug, Dr Lalchandani Labs Ltd's stock price is Rs. 25.52, having increased by 4.46% and recently reaching a 52-week high. The stock has significantly outperformed the Sensex over various periods, indicating strong investor sentiment and upward momentum.